Zaloguj się

Michael W. DeGregorio

Department of Internal Medicine,
Division of Hematology and Oncology,
Department of Internal Medicine, Division of Hematology and Oncology

University of California, Davis

BIOGRAPHY

Michael W. DeGregorio has not added Biography.

If you are Michael W. DeGregorio and would like to personalize this page please email our Author Liaison for assistance.

PUBLICATIONS

SERMs: current status and future trends.

Critical reviews in oncology/hematology Jul, 2002 | Pubmed ID: 12098608

Pharmacokinetics of selective estrogen receptor modulators.

Clinical pharmacokinetics , 2003 | Pubmed ID: 12648026

Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.

Menopause (New York, N.Y.) Mar, 2005 | Pubmed ID: 15772568

Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.

The Journal of steroid biochemistry and molecular biology Nov, 2005 | Pubmed ID: 16153821

Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.

Breast cancer research : BCR , 2005 | Pubmed ID: 16280035

Ineffectiveness of American ginseng in the prevention of dimethylbenzanthracene-induced mammary tumors in mice.

Oncology research , 2006 | Pubmed ID: 17476970

Pharmacologic effects of ospemifene in rhesus macaques: a pilot study.

Basic & clinical pharmacology & toxicology Jun, 2008 | Pubmed ID: 18346046

Pharmacologic evaluation of ospemifene.

Expert opinion on drug metabolism & toxicology Jun, 2010 | Pubmed ID: 20429673

Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.

Menopause (New York, N.Y.) Jan, 2012 | Pubmed ID: 21926925

Ospemifene, vulvovaginal atrophy, and breast cancer.

Maturitas Jan, 2013 | Pubmed ID: 23332519

Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.

Journal of translational medicine Mar, 2013 | Pubmed ID: 23496860

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.

International journal of women's health , 2013 | Pubmed ID: 24109197

INSTITUTIONS

University of California, Davis

JOVE ARTICLES

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Daniel P. Vang¹,

Gregory T. Wurz¹,

Stephen M. Griffey²,

Chiao-Jung Kao¹,

Audrey M. Gutierrez¹,

Gregory K. Hanson¹,

Michael Wolf³,

Michael W. DeGregorio¹

¹Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis,

²Comparative Pathology Laboratory, UC Davis School of Veterinary Medicine, University of California, Davis,

³Merck Serono Research, Merck KGaA, Darmstadt, Germany

Medicine

Prywatność

Warunki Korzystania

Zasady

Skontaktuj Się z Nami

Poleć Bibliotece

BIULETYNY JoVE

Badania

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archiwum

Edukacja

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centrum Zasobów Akademickich
Strona Wydziału

Autorzy

Przegląd
Proces Publikacji
Rada Redakcyjna
Zakres i Zasady
Recenzja ekspercka
FAQ
Prześlij

Bibliotekarze

Przegląd
Referencje
Subskrypcje
Dostęp
Zasoby
Biblioteczna Rada Doradcza
FAQ

O JoVE

Przegląd
Kierownictwo
Blog
JoVE Help Center
JoVE Sitemap

Michael W. DeGregorio

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Department of Internal Medicine,Division of Hematology and Oncology,Department of Internal Medicine, Division of Hematology and Oncology

University of California, Davis

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Department of Internal Medicine,
Division of Hematology and Oncology,
Department of Internal Medicine, Division of Hematology and Oncology